Fathi Mazouz
University of Paris
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Fathi Mazouz.
European Journal of Medicinal Chemistry | 1990
Fathi Mazouz; Luc Lebreton; René Milcent; Claude Burstein
Eighteen new 5-aryl-1,3,4-oxadiazol-2(3H)-one derivatives and sulfur analogues were prepared and evaluated in vitro for their inhibitory properties on monoamine oxidase (MAO) types A and B. The most active compounds in these series acted preferentially against MAO B with IC50 values in the range of 1.8-0.056 μM. The 5-(4-biphenylyl)-3-(2-cyanoethyl)-1,3,4-oxadiazol-2(3H)-one 23 and its oxadiazolethione analogue 33 were found to act as potent, selective and competitive MAO B inhibitors with a slight slow-binding character. Both compounds inhibited MAO A in a classical competitive manner. According to their Ki (MAO B) values of 2.6 and 4 × 10−8 M, respectively, and their Ki (MAO A)/Ki (MAO B) ratios of 270 and 500, respectively, 23 and 33 can be placed among the most active and selective competitive MAO B inhibitors known up to now. The structure-activity relationships are discussed.
European Journal of Medicinal Chemistry | 1988
Fathi Mazouz; Luc Lebreton; René Milcent; Claude Burstein
Abstract Monoamine oxidase (MAO) assay specificity based on substrate specificity was investigated by substrate competition experiments. 10 μM serotonin (5-HT) and 5 μM β-phenylethylamine (PEA) were found to ensure total substrate specificity for, respectively, MAO types A and B. Twenty-five 2-aryl-4 H -1,3,4-oxadiazin-5(6 H )-one derivatives were synthesized and tested in vitro for their inhibitory effects on MAO A and B. Most of them inhibited preferentially MAO B. The 2-(4-biphenylyl)-4-(2-cyanoethyl)-4 H -1,3,4-oxadiazin-5(6 H )-one 32 was the most efficient MAO B inhibitor and acted as a competitive inhibitor on the two enzymes. Its K i values for MAO A and B were 11 and 0.15 μM, respectively. Structure-activity relationships suggest that these oxadiazinones should interact with a hydrophobic site and a nucleophilic site on MAO B for binding, while the functional group of the N-4 substituent should compete with the substrate for the active site of the enzyme.
Journal of Medicinal Chemistry | 1993
Fathi Mazouz; Salah Gueddari; Claude Burstein; Daniel Mansuy; René Milcent
Journal of Medicinal Chemistry | 1995
Luc Lebreton; Olivier Curet; Salah Gueddari; Fathi Mazouz; Suzanne Bernard; Claude Burstein; René Milcent
Journal of Heterocyclic Chemistry | 1991
René Milcent; Géo Barbier; Beatrice Yver; Fathi Mazouz
European Journal of Medicinal Chemistry | 1990
Fathi Mazouz
Archive | 1989
René Milcent; Luc Lebreton; Fathi Mazouz; Claude Burstein; Salah Gueddari
Archive | 1989
René Milcent; Luc Lebreton; Fathi Mazouz; Claude Burstein; Salah Gueddari
Archive | 1992
René Milcent; Luc Lebreton; Fathi Mazouz; Claude Burstein; Salah Gueddari
Archive | 1988
René Milcent; Géo Barbier; Fathi Mazouz; Aziza Khaled Ben